Amgen has joined the wave of major drugmakers setting up direct-to-consumer programs amid President Donald Trump’s call for more DTC options to lower U.S. drug prices. The "AmgenNow" program, launched ...
The White House’s direct-to-consumer (DTC) platform, TrumpRx, is steadily expanding its catalogue, with products from GSK and Amgen the latest to join the collection of drugs offered through the pr | ...
LOS ANGELES (Reuters) -Amgen on Monday launched direct-to-consumer U.S. sales of its cholesterol medication Repatha at a discounted cash price, becoming the latest pharmaceutical company responding to ...
Amgen (NASDAQ:AMGN) said on Monday that it has launched its cholesterol medication, Repatha, directly to consumers in the U.S. at a reduced cash price. This move comes as part of a broader response ...
THOUSAND OAKS, Calif., Nov. 8, 2025 /PRNewswire/ -- Amgen (AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha ® (evolocumab) achieved ...
The FINANCIAL — Amgen on October 6 announced that Express Scripts will provide access to Repatha (evolocumab) through its national formulary. “Ensuring access to Repatha for appropriate patients is ...
Amgen's Repatha (evolocumab) has shown benefit in a long-term study in reducing cardiovascular incidents in patients without a prior history of heart attack or stroke. This comes several weeks after ...
(RTTNews) - Amgen (AMGN) announced detailed findings from its Phase 3 VESALIUS-CV clinical trial, revealing that Repatha (evolocumab) significantly reduces major adverse cardiovascular events (MACE) ...
Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never Had a Heart Attack or Stroke Real-World Evidence from the Repatha-CE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results